Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with Crohn's disease during anti TNF-α (infliximab) therapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Antibodies; Immunoglobulins; Infliximab

Criteria

Inclusion Criteria:

• •Pediatric patients who were diagnosed with severe Crohn's disease who require infliximab treatment

• confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological findings

Exclusion Criteria:

• •patients who has proven to have infliximab antibody